First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix - A phase II study

Gynecologic Oncology

Volumn 75, Issue 3, 1999, Pages 334-337

  Piver, M Steven ^a   Ghamande, Sharad A ^a   Eltabbakh, Gamal H ^b   O'Neill Coppola, Catherine ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION FIELD; RECURRENT CANCER; UTERINE CERVIX CANCER; VOMITING;

EID: 0032779057     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5586     Document Type: Article

References (12)

1. Landis, S, H, Murray, T, Bolden, S, Wingo, P, A: Cancer statistics48:6-31, 1998.
2. Alberts D S, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: an update. Semin Oncol. 18(S3):1998;11-24.
3. Thigpen T, Vance R B, Khansur T. The platinum compounds and paclitaxel in the management of carcinoma of the endometrium and the uterine cervix. Semin Oncol. 22 (S12):1995;67-72.
4. Thigpen T, Vance R, Khansur T, Malamud F. The role of paclitaxel in the management of patients with carcinoma of the cervix. Semin Oncol. 24(S2):1997;41-46.
5. Forsatiere A A. Use of taxol in squamous carcinoma of the head and neck. Semin Oncol. 20:1993;56-60.
6. McGuire W P, Blessing J A, Moore D, Lentz S S, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol. 14:1996;792-795.
7. Kudelka A P, Winn R, Edwards C L, Downey G, Greenberg H, Dakhil S R, Freedman R S, LoCoco S, Umbreit J, Delmore J E, Arbuck S, Loyer E, Gacrama P, Fueger R, Kavanagh J J. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-Cancer Drugs. 8:1997;657-661.
8. McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
9. Alberts D S, Kronmal R, Baker L H, Stock-Novak D L, Surwit E A, Boutselis J G, Hannigan E. Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group study. J Clin Oncol. 5:1987;1791-1795.
10. Omura G, Blessing J, Vaccarello L, Berman ML., Clarke-Pearson D L, Mutch D G, Anderson B. A randomized trial of cisplatin versus cisplatin + mitolactol versus cisplatin + ifosfamide in advanced squamous carcinoma of the cervix by the Gynecologic Oncology group. Gynecol Oncol. 60:1996;120-126.
11. Rose P G, Blessing J A, Gershenson D. Paclitaxel and cisplatin as first line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 72:1999;463.
12. McGuire, W, P, Arseneau, J, Blessing, J, A, Disaia, P, J, Hatch, K, D, Given, F, T, Nelson, N, HT, Creasman, W, T: A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the cervix. A Gynecologic Oncology Group study. J Clin Oncol, 7:1462-1468, 1989.